Cerdelga Leads to Sustained Benefits in Type 1 Gaucher Patients, Study Says
News
Long-term treatment with Cerdelga (eliglustat) safely and consistently lessens or stabilizes disease severity in adults with Gaucher disease type 1 (GD1), according to a six-year study in five patients. The findings are ... Read more